혈액종양 초진단 검사항목 지침 개정
Revision of Laboratory Testing Guidelines for Initial Diagnosis of Hematologic Neoplasms
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
대한진단혈액학회에서는 혈액종양환자를 대상으로 표준화된 진단 절차에 대한 임상 진료 권장사항을 제공할 수 있는 지침을 개 정하고자 하였다. WHO 개정 4판, National Comprehensive Cancer Network Guidelines, European LeukemiaNet recommendations을 포함한 국제 지침을 바탕으로 한 혈액종양 초진단 검사항 목 지침을 개정하였다. 본 개정 지침은 국내 혈액종양 진단에 유용 하게 활용되고 검사표준화에 기여하며 지속적인 협의 과정을 통 해 진단 알고리즘에 통합된 새로운 분자 기술 발전을 향상시킬 수 있을 것이다.
Abstract
The standardization committee of the Korean Society for Laboratory Hematology revised laboratory testing guidelines in order that hematologic neoplasms could be diagnosed according to the revised 4th edition of WHO classification of tumors of haematopoietic and lymphoid tissues . The new guidelines were revised based on an extensive review of international guidelines that included the National Comprehensive Cancer Network Guidelines, and European LeukemiaNet recommendations that are based on the revised WHO classification. We expect that the newly revised guidelines will improve clinical decisions, standardize laboratory tests, and enhance the development of new molecular technologies that are integrated into diagnostic algorithms via ongoing consensus initiatives.
참고문헌 (13)
- Swerdlow SH, "WHO classification of tumours of haematopoietic and lymphoid tissues" (2017), IARC
- 이자영, "혈액종양 초기진단 검사항목 지침", Laboratory Medicine Online, 6(1), pp.1~7 (2016), 대한진단검사의학회
- Radich JP, "Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology", J Natl Compr Canc Netw, 16, pp.1108~1135 (2018)
- Mesa RA, "NCCN guidelines insights: Myeloproliferative neoplasms, version 2.2018", J Natl Compr Canc Netw, 15, pp.1193~1207 (2017)
- Greenberg PL, "Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology", J Natl Compr Canc Netw, 15, pp.60~87 (2017)
- O’Donnell MR, "Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology", J Natl Compr Canc Netw, 15, pp.926~957 (2017)
- Brown PA, "NCCN guidelines insights: Acute lymphoblastic leukemia, version 1.2017", J Natl Compr Canc Netw, 15, pp.1091~1102 (2017)
- Kumar SK, "NCCN guidelines insights: Multiple myeloma, version 3.2018", J Natl Compr Canc Netw, 16, pp.11~20 (2018)
- Horwitz SM, "NCCN guidelines insights: Non-Hodgkin’s lymphomas, version 3.2016", J Natl Compr Canc Netw, 14, pp.1067~1079 (2016)
- Horwitz SM, "NCCN guidelines insights: T-cell lymphomas, version 2.2018", J Natl Compr Canc Netw, 16, pp.123~135 (2018)
- Hoppe RT, "NCCN guidelines insights: Hodgkin lymphoma, version 1.2018", J Natl Compr Canc Netw, 16, pp.245~254 (2018)
- Döhner H, "Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel", Blood, 129, pp.424~447 (2017)
- Heidel FH, "Managing myeloproliferative neoplasms evidence based on the ELN treatment recommendations 2018", Leukemia, 32, pp.1055~1056 (2018)